диссертации / 30
.pdf9.Остроумова О.Д., А.А.Зыкова Лечение артериальной гипертонии при метаболическом синдроме Трудный пациент, 2011; 12: стр. 4-9
10.Чукаева И.И. Значение воспалительных и иммунных реакций в течение инфаркта миокарда. //Дис. докт. мед. наук. - М. - 1990.
11.Чукаева И.И., Орлова Н.В., Алешкин В.А. Роль воспалительных процессов у больных с неинфекционными заболеваниями. // Инфекционные болезни. - 2007; 5(2): стр. 62-71.
12.Чукаева И.И., Орлова Н.В., Евдокимов Ф.А. Изучение влияния воспаления на прогноз острой кардиоваскулярной патологии. Пути коррекции. // Российский кардиологический журнал. - 2009; 5: стр. 30-35
13.Щеплев П.А. Гвасалия Б.Р. Поздний гипогонадизм, метаболический синдром и сердечно-сосудистая патология. // Лечащий врач. - 2009; 11:
стр.52-54.
14.Abdollahi A, Shoar TS. Hyperhomocysteinemia in HIV-Infected Individuals: Correlation of a Frequent Prothrombotic Factor with CD4+ Cell Count. // Oman Med J. - 2012; 27(3): pp. 224-227
15.Agerholm-Larsen B, Nordestgaard BG, Tybjærg-Hansen A. ACE Gene Polymorphism in Cardiovascular Disease. Meta-Analyses of Small and Large Studies in Whites. // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2000; 20: pp. 484-492.
16.Al – Ghamdi A, Jiman – Fatani AA, El-Banna. H. Role of Chlamidia pneumonie, Helicobacter pylory and Cytomegalovirus in coronary artery disease. // Pak. J. Pharm. Sci. - 2011; 24 (2): pp. 95-101.
17.Aramă V, Aramă SS, Daniela, Ion DA et al. Genetic Polymorphism and Pathogenic Factors Influencing the Risk of Metabolic Syndrome among HIV Infected Patients. // Therapeutics, Pharmacology and Clinical Toxicology. - 2009;
3(8): pp. 254-260.
18.Arildsen H, Sørensen KE, Ingerslev JM et al. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients
141
improve after initiation of highly active antiretroviral therapy. // HIV Med. -
2013;14(1): pp. 1-9.
19.Ariyo AA, Thach C, Tracy R. et al. Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly. // New England Journal of Medicine. – 2003; 349(22): pp. 2108-2115.
20.Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). // Muscle Nerve. - 2005; 32(3): pp. 247–60.
21.Baker J, Ayenew W, Quick H et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. // J Infectious Dis. - 2010; 201: pp. 285–292.
22.Barter PJ, Nicholls S, Rye KA et al. Antiinflammatory properties of HDL. // Circ Res. - 2004; 95(8): pp. 764-72.
23.Bernardino J, Merino J, Serrano L et al. Longitudinal comparison of inflammatory, coagulation and metabolic biomarkers in patients who start ART versus patients who remain ART-naı¨ve. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. // Journal of the International AIDS Society. – 2012; 15(4): pp.182-84
24.Bilhorn KR, Luo Y, Lee BT et al. High-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and cardiovascular disease in United States adults. // Am J Cardiol. - 2012; 110(10): pp. 1464-7.
25.Bitnun A, Sochett E, Babyn P et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIVinfected children. // AIDS. - 2003; 17(9): pp. 1319-27
26.Bitnun A, Sochett E, Dick PT. Insulin Sensitivity and β-Cell Function in Protease Inhibitor-Treated and -Naive Human Immunodeficiency Virus-Infected Children. // JCEM. - 2005; 90 (1): pp. 168174.
142
27.Blankenberg S, Luc G, Ducimetière P et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). // Circulation. - 2003; 108(20): pp. 2453-9.
28.Bobbert P., Weithäuser A., Andres J. et al.Increased plasma retinol binding protein 4 levels in patients with inflammatory cardiomyopathy. Eur J Heart Fail - 2009; 11 (12): pp. 1163-1168.
29.Calmy A, Gayet-Ageron A, Montecucco F. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. // AIDS. – 2009; - 23(8): pp. 929-39
30.Carr A, Grund B, Neuhaus J et al. Asymptomatic myocardial ischaemia in HIV-infected adults. // AIDS. – 2008; 22: pp. 257 – 267.
31.Carr A, Samaras K, Chisholm DJ et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. // Lancet. - 1998; 351(9119): pp. 1881–3.
32.Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. // Lancet. – 1999; 353: pp. 2093–2099.
33.Carr A. HIV protease inhibitor-related lipodystrophy syndrome. // Clin Infect Dis. - 2000; 2: pp. 135–42.
34.CASCADE Collaboration. Survival after introduction of HAART in peole witth known duration of HIV – infection. // Lancet, - 2000; 355: pp. 1158-1159.
35.Cesari M, Penninx BW, Newman AB et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). // Am J Cardiol. - 2003; 92(5): pp. 522-8.
36.Chang JJ, Altfeld M. TLR – mediated immune activation in HIV. // Blood. - 2009, 113 (2): 269-270
37.Chen JW, Gall MA, Deckert M et al. Increased serum concentration of von Willebrand factor in non-insulin dependent diabetic patients with and without diabetic nephropathy. BMJ, - 1995;311:1405
143
38.Chisteff N, Melchior JC, de Truchnis P et al. Increased serum interpheron alpha in HIV – 1 associated with lipodystrophy syndrome. // Eur Clin J Invest. - 2002; 32: pp. 43-50.
39.Danesh J, Collins R, Peto R et al. Lipoprotein (a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies. // Circulation. – 2000; 102: pp.1082-1085.
40.Daniyam CA, Iroezindu MO. Lipid Profile of Anti-Retroviral TreatmentNaive HIV-Infected Patients in Jos, Nigeria. // Annals of Medical and Health Sciences Research. – 2013; 3 (1): pp. 26-30.
41.Denue1 BA, Alkali1 MB, Abjah AU et al. Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen Infectious Diseases. // Research and Treatment. - 2013; 6: pp. 7–14.
42.Dhawan S, Puri RK, Kumar A. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. // Blood. - 1997; 90(4): pp. 1535–44.
43.Dolan SE, Hadigan C, Killilea KM et al., Increased Cardiovascular Disease Risk Indices in HIV-Infected Women. // J Acquir Immune Defic Syndr. - 2005; 39: pp. 44–54.
44.Domingo P, Matías-Guiu X, Pujol RM, et al. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in
patients with highly active antiretroviral therapy-associated lipodystrophy. //
J Infect Dis. - 2001;184(9): pp. 1197-201.
45.Dubé P.M. Disorders of Glucose Metabolism in Patients Infected with Human Immunodeficiency Virus. // Clin Infect Dis. - 2000; 3(6): pp. 1467-1475.
46.Duprez DA, Neuhaus J, Kuller LH et al. Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals. // PLoS ONE.- 2012; 7(9): e44454.
144
47.El-Sadr WM, Mullin CM, Carr A et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. // HIV Med. - 2005; 6(2): pp. 114-21.
48.Esser S, Gelbrich G, Brockmeyer N et al. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. // Clinical Research in Cardiology. - 2013, 102 (3): pp. 203-213.
49.Everett BM, Bansal S, Rifai N et al. Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. // Atherosclerosis. - 2009; 202(1): pp. 282-8.
50.Fisac C, Fumero E, Crespo M et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. // AIDS. - 2005; 19: pp. 917–925.
51.Friis-Moller N, Weber R; Reiss P. Results from the DAD study: Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. // AIDS. - 2003; 17(8): pp.1179-1193.
52.Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011.
53.Goldsmith D., Perry C. Atazanavir. Drugs. – 2003; 63: pp.1679-1693.
54.Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. // Biotherapy. - 1991; 3: pp. 143–58.
55.Grunfeld C, Kotler DP, Hamadeh R et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. // Am J Med. - 1989; 86: pp. 27–31.
56.Grunfeld C, Tien P. Difficulties in Understanding the Metabolic Complications of Acquired Immune Deficiency Syndrome. // Clinical Infectious Diseases. - 2003; 37 (2): pp. 43–6.
57.Hadigan C, Corcoran C, Stanley T et al. Fasting Hyperinsulinemia in Human Immunodeficiency Virus-Infected Men: Relationship to Body Composition, Gonadal Function and Protease Inhibitor Use. // J Clin Endocrinol Metab. - 2000; 85: pp. 35-41.
145
58.Hadigan C, Miller K, Corcoran C et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus–infected women. // J Clin Endocrinol Metab. - 1999; 84: pp. 1932–7.
59.Herbein G, Montaner L J, Gordon S. Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor. // J Virol. – 1996, 70 (11): рр. 7388-7397.
60.Hober D, Lucas B, Wattre P, Capron A, Haque A. TNF-alpha production by U937 promonocytes is enhanced by factors released from HIV-infected T4 lymphocytes: TNF-alpha is one of the mediators causing lysis of HIV-infected T4 cells. // Clin Immunol Immunopathol. – 1992, 62(2): рр.168-75.
61.Holeggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in LIFE study. // Kidney Int. - 2004; 65: pp. 1041-1049.
62.Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. // JAMA. - 2002; 288(16): pp. 2015-22.
63.Hsue PY, Hunt PW, Schnell A et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. // AIDS. - 2009; 23(9): pp. 1059-67.
64.Hu Y, Xu D, Sun C et al. Role of coagulation factor VII in pathogenesis of ischemic heart disease. // Journal of Huazhong University of Science and Technology. - 2006; 26(6): pp. 657-660.
65.Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. // Prog Lipid Res. - 2003;42(2): pp.81–92.
66.Iffen TS, Efobi H, Usoro CAO et al. Lipid Profile of HIV-Positive Patients Attending University of Calabar Teaching Hospital, Calabar – Nigeria. // World J. Med. Sci. - 2010, 5 (4): рр. 89-93.
146
67.Inoue T, Komoda H, Nonaka M et al, Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. // Int J Cardiol.- 2008; 124(3): pp. 319-25.
68.Islam FM, Wu J, Jansson J et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. // HIV Med. -2012; 13: pp. 453-468.
69.Jarrin I, Geskus, R, Bhaskaran K et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. // American journal of epidemiology. - 2008, 168(5): pp. 532-540.
70.Jefferis BJ, Papacosta O, Owen CG et al. Interleukin 18 and coronary heart disease: prospective study and systematic review. // Atherosclerosis. - 2011; 217(1): pp. 227-33.
71.Jeong SJ, Chin BS, Chae YT et al. Serum retinol-binding protein-4 levels are increased in HIV-infected subjects with metabolic syndrome receiving highly active antiretroviral therapy. // Yonsei Med J. – 2012, 53(6): pp. 1211-5.
72.Johansson L, Jansson JH, Boman K et al. Tissue Plasminogen Activator, Plasminogen Activator Inhibitor-1, and Tissue Plasminogen Activator/Plasminogen Activator Inhibitor-1 Complex as Risk Factors for the Development of a First Stroke. // Stroke. - 2000; 31: pp. 26-32.
73.Johnson JA, Albu J.A, Engelson ES et al. Incresed proinflammatory cytocine activity in HIV – infected subjects with lipodystrophy. // Am J Physiol Endocrinol Metab. - 2004: 286: pp. 261 – 271.
74.Jong E, Louw S, Meijers JC et al. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. // AIDS Patient Care STDS. - 2009; 23: pp. 1001–7.
75.Kanjanavanit S, Puthanakit T, Vibol U et al. High prevalence of lipid abnormalities among Antiretroviral-naïve HIV-infected Asian children with mild to moderate immunosuppression. // Antivir Ther. - 2011; 16(8): рр. 1351–1355
147
76.Kim KI, Oh SW, Ahn S et al. CRP level and HDL cholesterol concentration jointly predict mortality in a Korean population. // Am J Med. - 2012; 125(8): pp. 787-95.
77.Koenig W, Khuseyinova N, Baumert J et al., Increased concentrations of C- reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. // Arterioscler Thromb Vasc Biol.- 2006; 26(12): pp. 2745-51.
78.Kolovou GD, Anagnostopoulou KK. Apolipoprotein E polymorphism, age and coronary heart disease. // Ageing Res Rev. - 2007; 6(2): pp. 94-108.
79.Kotnik P, Keuper M, Wabitsch M et al. Interleukin-1β downregulates RBP4 secretion in human adipocytes. . PLoS One. 2013;8(2):e57796
80.Krishnan S, Schouten TJ, Atkinson B et al. Metabolic Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naïve HIV-Infected Individuals. // J Acquir Immune Defic Syndr. - 2012;61(3): pp. 381-389
81.Lane BR, Markovitz DM, Woodford NL et al. TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. // J Immunol. - 1999 ;163(7): pp. 3653-61.
82.Lang S, Mary-Krause M, Cotte L et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. // AIDS. - 2010; 24: pp. 1228-1230.
83.Lang S, Mary-Krause M, Simon A et al; French Hospital Database on HIV (FHDH)-ANRS CO4. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. // Clin Infect Dis. - 2012; 55: pp. 600-607.
84.Larranaga de GF, Petroni A, Deluchi G et al. Viral load and disease progression as responsible for endothelial activation and/or injury in human
148
immunodeficiency virus-1-infected patients. // Blood Coagul Fibrinolysis. - 2003;
14(1): pp. 15–8.
85.Ledwaba L, Tavel AJ, Paul Khabo P et al. Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. // PLoS One. - 2012; 7(3): e24243.
86.Leon ML, Zuckerman SH. Gamma interferon: a central mediator in atherosclerosis. // Inflamm Res. - 2005; 54: pp. 395-411.
87.Lepri АC, Pezzotti РP, Dorrucci M. et al. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. // BMJ. - 1994; 309: pp. 1537 -
88. Liang KW, Sheu WHH, Lee WL. Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand. // Can J Cardiol. - 2006; 22(8): pp. 691–696.
89.Lihn AS, Richelsen B, Pedersen SB et al. Increased expression of TNF-a, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. // American Journal of Physiology, Endocrinology and Metabolism. - 2003; 285: pp. 1072–1080.
90.Lijfering WM, Sprenger HG, Georg RR et al. Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection. // Clin Chem. - 2008; 54 (7): pp. 226-33.
91.Lowe GD, Yarnell JW, Sweetnam PM et al. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. // Thromb Haemost. -1998; 79(1): pp. 129-133.
92.Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. // PLoS Med. - 2006; 3(11):e442.
149
93.Meigs JB, Jacques PF, Selhub J et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study Diabetes Care.,- 2001;24(8):1403-10.
94.Meininger G, Hadigan C, Rietschel P et al. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. // Am J Clin Nutr. - 2002; 76: pp. 460–5.
95.Melenko SR, Sorokhan VD. Von Willebrand factor as a marker of
endothelium disfunction on patints with HIV/AIDS. // Материалы IV
международной научнопрактической конференции «Образование и наука».
София «БелГРАД-БГ». - 2010; 16: стр.56-59.
96.Mildvan D, Machado SG, Wilets I et al. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. // Lancet. - 1992; 339: pp. 453–6.
97.Milionis A, Milionis C. Correlation between LDL-cholesterol and C-reactive protein among an apparently healthy population in the city of Athens. // Health, - 2011; 3 (6): pp. 338-342.
98.Miller TL, Borkowsky W, DiMeglio LA et al. Metabolic Abnormalities and Viral Replication is Associated with Biomarkers of Vascular Dysfunction in HIVInfected Children. // HIV Med. - 2012; 13(5): pp. 264–275.
99.Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994-1998: the EuroSIDA study. // Lancet. - 2000, 356: pp. 291-296
100.Mocroft A, Reiss P, Gasiorowski J et al. Serious fatal and nonfatal non- AIDS-defining illnesses in Europe. // J Acquir Immune Defic Syndr. - 2010; 55: pp. 262-270.
101.Mu H, Chai H, Lin PH et al. Current update on HIV-associated vascular disease and endothelial dysfunction. // World J Surg. - 2007; 31(4): pp. 632–43.
102.Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body
150